N@N

Dynasil Corporation Announces Approval of Key Patents for Medical Imaging and Detecting Nuclear Materials

^{Published on 2011-02-10 06:30:54 - Market Wire}
 

WATERTOWN, Mass.--([ BUSINESS WIRE ])--Dynasil Corporation (NASDAQ:DYSL), a leader in specialized sensors, precision instruments and optical products for the medical, industrial and homeland security/defense markets, today announced that its subsidiary, Radiation Monitoring Devices, Inc. (RMD) was granted eleven individual patents by the United States Patent and Trademark Office (USPTO) during 2010 relating to new scintillation materials for improved nuclear material detection and medical imaging applications. These patents cover technology that can help protect the public against the risk of nuclear terrorism by providing greater sensitivity in security scanning systems. The same technology can also help doctors improve patient outcomes, such as by more accurately locating cancer cells for targeted therapy through higher resolution medical imaging, with lower radiation doses.

"They reflect the depth of knowledge and experience of our people and their commitment to deliver important solutions to our country and to create substantial and lasting value for our customers and shareholders."

aThese patents further enhance Dynasila™s position in the rapidly growing security scanning and medical imaging marketplaces,a said Craig T. Dunham, CEO of Dynasil. aThey reflect the depth of knowledge and experience of our people and their commitment to deliver important solutions to our country and to create substantial and lasting value for our customers and shareholders.a

Both the security and imaging segments are expected to have high growth potential. According to the Civitas Group, the radiation and radiological security industry has a market size of about $300 million per year. The global PET and SPECT medical imaging market is expected to grow from an estimated $6.5 billion in 2010 to $10.3 billion in 2015, according to a recent report published by the firm MarketsandMarkets.

Nine of these new patents primarily relate to scintillator materials (US patent numbers 7,655,919, 7,696,482, 7,700,920, 7,723,687, 7,755,054, 7,759,645, 7,772,558, 7,847,262, and 7,854,961), which are at the heart of instruments and systems used to sense radiation, determine its energy, identify its source and therefore enable the detection, measurement and imaging of radiation in medical, security and industrial settings. The other two granted patents (US patent numbers 7,828,926 and 7,692,156) are for new scintillator manufacturing methods to optimize their performance and costs. Importantly, these novel technologies have the potential for widespread use in homeland security, medical and commercial applications.

About Radiation Monitoring Devices, Incorporated

RMD is recognized internationally as a leading innovator, at the forefront of specialized materials and instrumentation research and development, particularly in advanced scintillator and semiconductor materials and in related devices and instrumentation developed for and applied to demanding applications in healthcare, defense, homeland security, research and industry.

About Dynasil Corporation of America (NASDAQ:DYSL)

Dynasil is a provider of technology, products, services and solutions aimed at making the world safer and healthier.The Company supplies a broad range of customers by serving their specific needs in the medical, industrial, and homeland security/defense markets.Dynasil has operations in Massachusetts, New Jersey, New York and the UK.

This news release may contain forward-looking statements usually containing the words "believe," "expect," aplana, atargeta, aintenda or similar expressions.These statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act.Future results of operations, projections, and expectations, including those related to the size and growth of the markets described in this release, involve certain risks and uncertainties that could cause actual results to differ materially from the forward-looking statements.Factors that would cause or contribute to such differences include, but are not limited to, the factors detailed in the Company's Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, as well as in the Company's other Securities and Exchange Commission filings, continuation of existing market conditions and demand for our products.